Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-SALT: Grazoprevir + Elbasvir in HCV with CP-B Cirrhosis
NCT02115321Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
01
Overview
Phase 3, open-label trial of grazoprevir and elbasvir in hepatitis C (HCV) (4 arms), sponsored by Merck & Co. Primary endpoints: Sustained Viral Response 12 Weeks After Completing Study Therapy at 24 weeks, Number of Participants Experiencing an Adverse Event at 14 weeks and 1 more. Started May 2014; status: completed.
02
Drugs
grazoprevirelbasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02115321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02115321.